# OnCo record checkmate-9la (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-9la/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-9la", "NCT03215706" ;
  schema:name "CheckMate 9LA"@en ;
  schema:description "Used just two cycles of chemotherapy to cover the first weeks while dual immunotherapy takes effect, an answer to the criticism that immunotherapy alone is too slow for people with heavy disease."@en ;
  schema:url <https://onco.cc/trials/checkmate-9la/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03215706>, <https://doi.org/10.1016/S1470-2045(20)30641-0>, <https://www.nice.org.uk/guidance/ta724> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/immune-checkpoint/>, <https://onco.cc/terms/tps/> ;
  onco:trials <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/trials/nct03164616/> .